Juno Therapeutics

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.
Type
Public
HQ
Seattle, US
Founded
2013
Size (employees)
533 (est)+43%
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US

Key People at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO

Juno Therapeutics Office Locations

Juno Therapeutics has offices in Seattle, Washington, Bothell, Waltham and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N

Juno Therapeutics Data and Metrics

Juno Therapeutics Financial Metrics

Juno Therapeutics's revenue was reported to be $79.4 m in FY, 2016 which is a 336% increase from the previous period.
$, USD

Revenue (FY, 2016)

79.4 m

Revenue growth (FY, 2015 - FY, 2016), %

336%

Net income (FY, 2016)

(245.6 m)

EBIT (FY, 2016)

(255.6 m)

Market capitalization (23-Jun-2017)

3 b

Closing share price (23-Jun-2017)

27

Cash (31-Dec-2016)

187.9 m
Juno Therapeutics's current market capitalization is $3 b.
$, USDFY, 2015FY, 2016

Revenue

18.2 m79.4 m

Revenue growth, %

336%

R&D expense

46.2 m264.3 m

General and administrative expense

4.2 m70.7 m

Operating expense total

51.7 m335 m

EBIT

(51.7 m)(255.6 m)

EBIT margin, %

(284%)(322%)

Pre tax profit

(51.8 m)(256.2 m)

Income tax expense

2.8 m10.7 m

Net Income

(51.8 m)(245.6 m)
$, USDFY, 2015FY, 2016

Cash

252.4 m187.9 m

Accounts Receivable

315 k13.3 m

Inventories

8.4 m26.5 m

Current Assets

951.8 m772.3 m

PP&E

42.1 m81.7 m

Goodwill

122.1 m221.3 m

Total Assets

1.4 b1.3 b

Accounts Payable

4.2 m4.4 m

Current Liabilities

119.7 m114.9 m

Additional Paid-in Capital

1.7 b1.9 b

Retained Earnings

(585.7 m)(831.2 m)

Total Equity

1.1 b1.1 b

Financial Leverage

1.3 x1.3 x
$, USDFY, 2015FY, 2016

Net Income

(51.8 m)(245.6 m)

Depreciation and Amortization

2 k14.2 m

Accounts Receivable

33 k(13 m)

Accounts Payable

(2.7 m)3.7 m

Cash From Operating Activities

(103.6 m)(189.8 m)

Purchases of PP&E

(42 k)(56.2 m)

Cash From Investing Activities

(42 k)88.6 m

Cash From Financing Activities

66.5 m36.8 m
$, USDY, 2016

Revenue/Employee

212.8 k

Financial Leverage

1.3 x

Juno Therapeutics Operating Metrics

Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016
FY, 2016

Patents (US)

72

Patent Applications

481

Patents (foreign)

86

Juno Therapeutics Market Value History

Juno Therapeutics Job Categories

Juno Therapeutics Online and Social Media Presence

Juno Therapeutics News and Updates

Juno Therapeutics Company Life and Culture

You may also be interested in